Check SCREEN READER MODE to make this survey compatible with screen readers.
Next Generation Clinical Mass Spectrometry – International Survey
Introduction
The IFCC Emerging Technology Division (ETD), along with the Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) and the Australasian Association for Clinical Biochemistry and Laboratory Medicine (AACB) values your insights as an IFCC key voice.
Building on our 2024 questionnaire (PMID: 4102995), this survey is the next step in our (IFCC-ETD-APFCB-AACB) ongoing effort to advance clinical mass spectrometry practices.
The collective results will:
- Identify gaps between current laboratory needs and emerging technologies; - Inform manufacturers regarding real-world clinical demands; - Enable evidence-based dialogue on “Next Generation Clinical Mass Spectrometry".
Why your input matters:
Your feedback is essential for bridging the gap between today’s challenges and tomorrow’s solutions. By participating, you help us advocate for the resources and technological shifts necessary to ensure the next generation of mass spectrometry is built for the practical needs of the clinical laboratory.
The survey consists of 27 questions and will take approximately 10 minutes to complete.
Thank you for your insights
Please submit your response by 7 June 2026.
All submitted data will be treated as confidential and used solely for above described purposes.
